Printer Friendly

Akorn, Inc. Announces First Post-Inspection Product Approval for Decatur Manufacturing Facility.

BUFFALO GROVE, Ill. -- Akorn, Inc. (AMEX:AKN) today announced that it has received an ANDA approval for Brimonidine Ophthalmic Solution. This is the first new product approval received by the Company since its successful cGMP inspection that occurred in the third quarter of 2005.

Arthur S. Przybyl, Akorn's President and Chief Executive Officer stated, "We are pleased to announce this new product approval. This product is representative of several other product submissions that are currently undergoing review by the FDA. The group of products currently undergoing review were all submitted through our Decatur manufacturing facility."

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock.

Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 20, 2006
Words:491
Previous Article:Williams-Sonoma, Inc. Provides Financial Guidance for Fiscal Year 2006; Revenues Projected to Increase 10.1% to 12.1% -- Diluted EPS Projected to...
Next Article:Sharp Electronics to Add Capacity to Large-Format LCD Panel Production Line at Kameyama Plant No. 1 in Japan.
Topics:


Related Articles
Akorn, Inc. and Hameln Pharmaceuticals gmbh Announce the Signing of an Exclusive Binding Term Sheet to License and Supply to Akorn two Orphan Drug...
Obituaries.
Akorn, Inc. Announces FDA Inspection Results.
Akorn, Inc. Reports Year End 2005 Results and Provides Outlook for 2006.
Akorn, Inc. Announces Supplemental New Drug Application Approval for Inapsine (R).
Akorn, Inc. Announces Supplemental New Drug Application Approval for Sufenta(R).
Akorn, Inc. Announces Product Approval for Amiodarone Hydrochloride Injection.
Akorn, Inc. Announces Product Approval For Diltiazem Hydrochloride Injection.
Alcoa's Hungary operation ships first order of turbine airfoils.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters